Minireviews
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2014; 6(4): 448-457
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.448
Kallikrein-kinin in stem cell therapy
Julie Chao, Grant Bledsoe, Lee Chao
Julie Chao, Grant Bledsoe, Lee Chao, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, United States
Author contributions: Chao J reviewed the literature, conceived the paper and wrote the paper; Bledsoe G reviewed the literature, conceived the paper and wrote the paper; Chao L reviewed the literature, conceived the paper and wrote the paper.
Supported by National Institutes of Health, No. HL118516, HL29397 and HL44083
Correspondence to: Julie Chao, PhD, Professor, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC 29425, United States. chaoj@musc.edu
Telephone: +1-843-7929927 Fax: +1-843-7924850
Received: July 22, 2014
Revised: August 27, 2014
Accepted: August 30, 2014
Published online: September 26, 2014
Core Tip

Core tip: Tissue kallikrein-kinin exerts beneficial actions in the cardiovascular, renal and central nervous systems. Recent studies demonstrated that genetic modification of mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) by tissue kallikrein provides enhanced protection against renal ischemia/reperfusion, lupus nephritis, myocardial infarction and hindlimb ischemia. Tissue kallikrein stimulates the proliferation, viability, migration and functional activity of cultured MSCs, EPCs and neural stem cells. Moreover, plasma kallikrein-kinin augments EPC mobility and function in arthritis, whereas the cleaved kininogen product of plasma kallikrein inhibits EPC viability and tube formation. Thus, kallikrein-kinin may enhance the efficacy of stem cell therapy for human diseases.